Back to Search
BETH OVERMOYER, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1801827209Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
043266(CT)234514(MA)
Research & Publications (20)
Options for the treatment of patients with taxane-refractory metastatic breast cancer.
PMID 18637401·Clin Breast Cancer·2008
6-review
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
PMID 17908980·Clin Cancer Res·2007
3-trial
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
PMID 19417018·Clin Cancer Res·2009
3-trial
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
PMID 18414865·Cancer Chemother Pharmacol·2009
3-trial
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
PMID 18490651·J Clin Oncol·2008
3-trial
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules.
PMID 16969707·Invest New Drugs·2007
3-trial
Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
PMID 16344915·Breast Cancer Res Treat·2006
3-trial
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
PMID 15681523·J Clin Oncol·2005
3-trial
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
PMID 16110015·J Clin Oncol·2005
3-trial
Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
PMID 16001993·Clin Breast Cancer·2005
3-trial
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
PMID 15955900·J Clin Oncol·2005
3-trial
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
PMID 15684311·J Clin Oncol·2005
3-trial
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
PMID 15538570·Cancer Chemother Pharmacol·2005
3-trial
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
PMID 15717740·Semin Oncol·2004
6-review
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
PMID 14734457·Clin Cancer Res·2004
3-trial
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
PMID 12885806·J Clin Oncol·2003
3-trial
Combination chemotherapy for metastatic breast cancer: reaching for the cure.
PMID 12586790·J Clin Oncol·2003
6-review
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
PMID 12067983·Cancer Res·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, MAYER 220B
BOSTON, MA 02115 - Phone
- (617) 632-3427
Quick Facts
- NPI
- 1801827209
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile